The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan.

First-quarter 2020 earnings reports are coming out, the stock market remains volatile and much of the world is still on lockdown. In this challenging environment, there are business opportunities abound, “but investors are taking a hard look at their checkbooks,” Keith Bliss, managing partner and CEO of iQ Capital, told BioSpace.

Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field, according to Atlas Venture partner Bruce Booth.

Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bayer shares fell by as much as 5 percent after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations the company’s Roundup weed killer causes cancer.

The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.

Top 10 Pipelines To Watch: 2019 Annual Report

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.

Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.